China’s NHSA and NHC Issue Guidelines to Enhance Volume-based Procurement Mechanism
The National Healthcare Security Administration (NHSA) and National Health Commission (NHC) of China have released...
Policy / Regulatory
NMPA Releases 85th Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 85th batch of reference drugs for...
China’s Health Commission Issues Guidelines to Strengthen Ties Between Healthcare and Elderly Care
The National Health Commission, in conjunction with three other bureaus, has issued the “Notice on...
Hefan Medicine’s Piracetam Production and Marketing Suspended Over GMP Violations
The National Drug Alliance Procurement Office has issued a notification to suspend the manufacturing and...
China’s NHC Launches Pilot Plan to Expand Wholly Foreign-Owned Hospital Sector
The National Health Commission (NHC) has released the “Pilot Work Plan for Expanding the Wholly...
NMPA Drafts Medical Representative Management Measures, Seeks Public Input
The National Medical Products Administration (NMPA) has released the “Medical Representative Management Measures (draft proposal)”,...
Chinese Pharmacopoeia Commission Approves Draft for ChP 2025 Edition
On December 27, the 12th Conference of the Chinese Pharmacopoeia Commission (ChPC) Executive Committee concluded...
National Reimbursement Drug List 2024 Expands Coverage with 91 New Drugs
The National Medical Products Administration has released the finalized National Reimbursement Drug List (NRDL) for...
China’s NHC Aims to Enhance Continuity of Medical Services with Referral System by 2030
The National Health Commission (NHC) has released a notification aimed at enhancing the continuity of...
NHSA Issues Guidelines to Suspend Direct Online Listing of In-Shortage Drugs
The National Healthcare Security Administration (NHSA) has issued the “Guidelines for Risk Management of In-Shortage...
NHC Aims for Nationwide Inspection Result Sharing in Medical Consortia by 2030
The National Healthcare Commission (NHC) has issued the “Guiding Opinions on Further Promoting Mutual Recognition...
AstraZeneca’s ALXN1850 (Efzimfotase Alfa) Selected for China’s Rare Disease Care Plan
The Center for Drug Evaluation (CDE) in China has announced its intention to include AstraZeneca’s...
NHSA to Announce NRDL Adjustment Results at November 28th Press Conference
The National Healthcare Security Administration (NHSA) will unveil the results of the negotiation and price...
NMPA and Local Governments Streamline Drug Approval Processes in China
The National Medical Products Administration (NMPA) has released a notification regarding the pilot work for...
National Allied Procurement Office Announces Round 10 VBP Tender Program with New Rules
The National Allied Procurement Office has released a notification regarding Round 10 of the national...
Jiangsu Chia Tai Fenghai’s ALS Treatment FHND1002 Selected for CDE’s Patient-Centered Care Plan
China’s Center for Drug Evaluation (CDE) has announced its intention to include Jiangsu Chia Tai...
China’s NHC Sets Sights on Enhancing Grassroots Drug Management and Access
The National Health Commission (NHC) has issued a set of opinions designed to accelerate the...
NMPA Launches ‘Medical Service Price Items’ Column with Comprehensive Sub-Sections
The National Medical Products Administration (NMPA) has taken a significant step towards enhancing transparency in...
NMPA’s CDE Issues Guidelines for Leveraging Real-World Data in Drug Regulation
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has released...
Merck Secures Exclusive Rights to LaNova’s PD-1/VEGF Bispecific Antibody LM-299
US pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced a significant...